Bryan Dechairo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bryan Dechairo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Christopher C Overall
Myriad Genetics Inc., Salt Lake City, UT 84108, USA
1 shared publicationDaniel Grima
Cornerstone Research Group Inc., Burlington, ON, L7N 3H8, Canada
1 shared publicationHolly Johnson
Department of Medical Affairs, Myriad Neuroscience, Mason, OH 45040, USA
1 shared publicationJames Li
Department of MMM Informatics, Myriad Genetics, Mason, OH 45040, USA
1 shared publicationJulian Nam
Hoffmann-La Roche Ltd, Mississauga, ON, L5N 5M8, Canada
1 shared publication- Julie-Anne Tanner
Myriad Neuroscience
1 shared publication
Latest Publications
- Open Access
- 17 April 2020
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 559-569
The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions...
- 17 April 2020
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 559-569
Open AccessThe Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions...
- Open Access
- 17 April 2020
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 521-531
Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective
Aim: Evaluate cost–effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcar...
- 17 April 2020
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 521-531
Open AccessCost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective
Aim: Evaluate cost–effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcar...